Halozyme stock outlook positive as Citizens JMP reaffirms $91 target

Citizens JMP reiterated its Market Outperform rating and $91 price target for Halozyme Therapeutics (HALO), following the final CMS guidance for 2028 IRA Medicare drug price negotiations. This guidance, which made no changes to the combination drug policy, is viewed as a "clear win" for Halozyme's ENHANZE technology, alleviating prior investor concerns that had pressured shares. The firm underscored Halozyme's robust financial health, including 35% revenue growth, and expressed confidence in ENHANZE's continued clinical benefit and royalty stability.

Analysis

A significant regulatory overhang for Halozyme Therapeutics (HALO) has been removed following the finalization of the CMS guidance for 2028 IRA Medicare drug price negotiations. The guidance, which makes no changes to the pre-existing combination drug policy, is being interpreted by analysts as a 'clear win' for Halozyme's ENHANZE technology, alleviating investor concerns that had previously pressured the stock. This positive development is supported by the company's robust financial health, demonstrated by a perfect Piotroski Score of 9 and 35% revenue growth over the last twelve months. The sentiment is echoed across Wall Street, with multiple firms upgrading ratings or raising price targets; Citizens JMP reiterated a Market Outperform with a $91 target, Benchmark raised its target to $90, and Morgan Stanley upgraded the stock to Overweight. These actions were prompted by the favorable CMS news, strong H1 2025 earnings that beat estimates, and positive developments such as Merck's FDA approval for subcutaneous Keytruda, which utilizes ENHANZE. While the consensus is strongly positive, Goldman Sachs maintains a more cautious Neutral rating, raising its target to $56 while noting potential long-term impacts from the Inflation Reduction Act, representing a minority but notable dissenting view.

Key Decisions for Investors

• The favorable CMS ruling significantly de-risks the near-term outlook for Halozyme's ENHANZE royalty stream, warranting a re-evaluation of the stock now that a key uncertainty has been resolved.
• Given the combination of strong fundamentals, including 35% revenue growth and upwardly revised 2025 guidance, and a broad-based increase in analyst price targets, investors may consider this a strong confirmation of a bullish thesis.
• Despite the positive momentum, it is prudent to monitor any future CMS policy discussions for 2029 and remain aware of the potential long-term risks associated with the Inflation Reduction Act, as highlighted by Goldman Sachs' more cautious stance.